|Security||GSUM / Gridsum Holding Inc. (398132100)|
|Institutional Owners||41 (2 N-Q Owners)|
|Institutional Shares||60,462,155 (ex. N-Q)|
|Institutional Value||$ 40,241,000 USD (ex. N-Q)|
Institutional Stock Ownership and Shareholders
Gridsum Holding Inc. (NASDAQ:GSUM) has 41 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 60,462,155 shares.
Largest shareholders include
Steamboat Ventures Asia, L.P., Qi Guosheng, Futurex Innovation Spc, Moon Capital Management Lp, Light Street Capital Management, Llc, Guofa Yu, Wells Fargo & Company/mn, FIL Ltd, Capital Research Global Investors, and Federated Investors Inc /pa/.
Gridsum Holding Inc. (NASDAQ:GSUM) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/gsum"><img src="https://images.fintel.io/us-gsum-so.png" alt="GSUM / Gridsum Holding Inc. Institutional Ownership"><a>
|Global X Management CO LLC||4,648||38|
|FEDERATED INVESTORS INC /PA/||300,000||300,000||0.00||2,745||2,451||-10.71|
|D. E. Shaw & Co., Inc.||0||11,293||0||92|
|Federated Equity Funds (see advisory)|
|PICTET ASSET MANAGEMENT LTD||90,868||0||-100.00||831||0||-100.00|
|UBS Group AG||1,210||383||-68.35||11||3||-72.73|
|Steamboat Ventures Asia, L.P.||3,470,052||34,700,529||900.00|
|REGIONS FINANCIAL CORP||100||100||0.00||1||1||0.00|
|LIGHT STREET CAPITAL MANAGEMENT, LLC||1,752,657|
|DEUTSCHE BANK AG\||573||20,611||3,497.03||5||168||3,260.00|
|12 West Capital Management LP||220,088||0||-100.00||2,267||0||-100.00|
|GROUP ONE TRADING, L.P.||62,682||512|
|ROYAL BANK OF CANADA||300||0||-100.00||3||0||-100.00|
|WHALEROCK POINT PARTNERS, LLC||68,400||55,135||-19.39||626||450||-28.12|
|Capital Research Global Investors||1,005,000||1,005,000||0.00||9,196||8,211||-10.71|
|INDUS CAPITAL PARTNERS, LLC||115,797||279,323||141.22||1,060||2,282||115.28|
|MILLENNIUM MANAGEMENT LLC||89,309||228,157||155.47||817||1,864||128.15|
|TIAA CREF INVESTMENT MANAGEMENT LLC||10,907||0||-100.00||100||0||-100.00|
|CREDIT SUISSE AG/||47,971||391|
|Powershares Exchange Traded Fund Trust (see advisory)|
|JP Morgan Chase & Co||346||0||-100.00||3||0||-100.00|
|WELLS FARGO & COMPANY/MN||1,265,927||1,282,627||1.32||11,584||10,479||-9.54|
|PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO||5,000||4,200||-16.00||46||34||-26.09|
|MATTHEWS INTERNATIONAL CAPITAL MANAGEMENT LLC||467,447||0||-100.00||4,815||0||-100.00|
|WOLVERINE TRADING, LLC||Call||33,200||271|
|NEW SILK ROAD INVESTMENT PTE LTD||53,600||0||-100.00||552||0||-100.00|
|BANK OF AMERICA CORP /DE/||25||109||336.00||0||1|
|ASHFORD CAPITAL MANAGEMENT INC||10,000||82|
|Quantitative Systematic Strategies LLC||11,360||11,024||-2.96||104||90||-13.46|
|Athos Capital Ltd||83,538||160,461||92.08||764||1,311||71.60|
|BOOTHBAY FUND MANAGEMENT, LLC||14,705||120|
|WOLVERINE TRADING, LLC||Put||34,100||279|
|SOROS FUND MANAGEMENT LLC||150,000||0||-100.00||1,373||0||-100.00|
|SPRINGBOK CAPITAL MANAGEMENT, LLC||26,959||220|
|Cutler Group LP||Call||1,800||0|
|SIMPLEX TRADING, LLC||9,725||79|
|CITADEL ADVISORS LLC||10,282||0||-100.00||94||0||-100.00|
|DRIEHAUS CAPITAL MANAGEMENT LLC||742,827||0||-100.00||7,651||0||-100.00|
|SUSQUEHANNA INTERNATIONAL GROUP, LLP||Call||54,300||444|
|ELLINGTON MANAGEMENT GROUP LLC||22,400||0||-100.00||205||0||-100.00|
|MOON CAPITAL MANAGEMENT LP||2,360,859|
|Herald Investment Management Ltd||100,000||100,000||0.00||915||815||-10.93|
|GOLDMAN SACHS GROUP INC||68,995||0||-100.00||631||0||-100.00|
|Centerstar Asset Management, Llc||39|
|QUENTEC ASSET MANAGEMENT LLC||760,562||0||-100.00||6,959||0||-100.00|
|WOLVERINE TRADING, LLC||26,205||214|
|Cutler Group LP||2,000||16|
|STATE STREET CORP||35,300||28,800||-18.41||323||235||-27.24|
|Futurex Innovation Spc||6,153,846|
|NORTHERN TRUST CORP||15,019||12,007||-20.05||137||98||-28.47|
We have recently started to include coverage of N-Q filers in our ownership database. N-Q forms are unstructured and difficult for machines to parse into accurate financial data.
However, Because of the large number of these institutions and this difficulty in tracking their positions, they represent a significant, yet hidden, market force. In an effort to widen our ownership coverage and provide greater transparency, we are testing various ways to expose these owners in an accurate manner. This early version of the crawler simply identifies mentions of companies in the N-Q forms.
- We only list underlying securities (the ordinary shares), even though the actual security held might be a derivative or a related bond issue. For example, although the institution is shown on this security page ( GSUM / Gridsum Holding Inc. ), the institution may actually own a related security such as a preferred share or a bond. To find out the exact security, click on the institution link and then follow the link to the actual "N-Q".
- We only list fund sponsors as institutions, even though the security might be held within a fund operated by the listed institution.. For example, the institution listed in the table as the owner is probably a sponsor of a family of ETFs or mutual funds. If so, then this security is owned by a fund or several funds within the family, and not directly owned by the listed institution. The crawler is not yet able to place these holdings within the individual funds. Atain, you must review the actual filing to see the detail.
These limitations are significant but we believe that the increased transparency outweights the limitations. Future revisions of the crawler will resolve these limitations. Use this information at your own risk!
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
Related News Stories
* GRIDSUM HOLDING - ON APRIL 30, 2018, ENTERED CONVERTIBLE NOTE PURCHASE AGREEMENT WITH FUTUREX INNOVATION SPC (0-4)
GSUM believes it is currently the technology market leader in the China enterprise-focused AI space with a global best-of-breed enterprise-AI engine. (253-4)
as of ET